Ionis Pharmaceuticals Inc.
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $507.7M | $346.6M | $283.7M | $214.2M | $147.3M | $102.0M | $99.1M | $108.5M |
| Cost of Revenue | $0 | $0 | — | — | — | — | — | — |
| Gross Profit | $507.7M | $346.6M | — | — | — | — | — | — |
| Gross Margin | 100.0% | 100.0% | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $372.5M | $340.4M | $319.5M | $238.9M | $173.7M | $154.6M | $153.1M | $145.2M |
| SG&A Expense | $108.5M | $48.6M | $37.2M | $20.1M | $14.9M | $12.5M | $12.8M | $11.7M |
| Operating Income | $31.0M | $-20.2M | $-75.8M | $-47.7M | $-51.7M | $-68.9M | $-71.1M | $-48.4M |
| Operating Margin | 6.1% | -5.8% | -26.7% | -22.3% | -35.1% | -67.5% | -71.8% | -44.6% |
| Interest Expense | $44.8M | $38.8M | $36.7M | $22.2M | $19.4M | $21.2M | $16.7M | $13.2M |
| Pretax Income | $-16.8M | $-83.6M | $-87.9M | $-54.4M | $-66.6M | $-74.6M | $-84.8M | $-61.2M |
| Income Tax Expense | $-6.0M | $2.9M | $372.0K | $-15.4M | $-5.9M | $-9.1M | $11.0K | $92.0K |
| Net Income | $346.0K | $-60.4M | $-88.3M | $-39.0M | $-60.6M | $-65.5M | $-84.8M | $-61.3M |
| Net Margin | 0.1% | -17.4% | -31.1% | -18.2% | -41.2% | -64.2% | -85.6% | -56.5% |
| EPS (Basic) | $0.15 | $-0.50 | $-0.74 | $-0.33 | $-0.55 | $-0.65 | $-0.85 | $-0.62 |
| EPS (Diluted) | $0.15 | $-0.50 | $-0.74 | $-0.33 | $-0.55 | $-0.65 | $-0.85 | $-0.62 |
| Shares Outstanding (Basic) | 124.0M | 120.9M | 119.7M | 118.4M | 110.5M | 100.6M | 99.7M | 99.1M |
| Shares Outstanding (Diluted) | 126.1M | 120.9M | 119.7M | 118.4M | 110.5M | 100.6M | 99.7M | 99.1M |
| Dividends Per Share | — | — | — | — | — | — | — | — |